MedTrace Logo

Personalized Antiplatelet Secondary Stroke PRevenTion

NCT03979781 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2023-12-15

No results posted yet for this study

Summary

This is a descriptive study designed to evaluate the safety and feasibility of a precision medicine approach to antiplatelet selection for secondary stroke prevention.

Conditions

Interventions

DRUG

tailored antiplatelet selection

antiplatelet selection guided by platelet function phenotype and/or key pharmacogene genotypes

DRUG

standard of care

antiplatelet selection using standard of care

Sponsors & Collaborators

  • State University of New York - Upstate Medical University

    lead OTHER

Principal Investigators

  • Karen C Albright, PhD, DO · State University of New York - Upstate Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-11
Primary Completion
2023-05-09
Completion
2023-05-09
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03979781 on ClinicalTrials.gov